No Data
No Data
Earnings Preview: VRNA to Report Financial Results Pre-market on April 29
New Analyst Forecast: $VRNA Given $80.0 Price Target
Analysts Conflicted on These Healthcare Names: Verona Pharma (VRNA), Neogen (NEOG) and ANI Pharmaceuticals (ANIP)
Cantor Fitzgerald Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $80
Cantor Fitzgerald Initiates Verona Pharma at Overweight
Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of New COPD Drug Ohtuvayre